Abstract
Aim: Different studies have been performed to investigate stem cell administration as a promising tool for recovery of injured tissue in multiple sclerosis (MS), the most common demyelinating disease.
Methods: In the present systematic review, the electronic databases of PubMed and ScienceDirect were searched to screen English language studies published until April 2020.
Results: The results obtained from experimental autoimmune encephalomyelitis (EAE) animals revealed that modified mesenchymal stem cells (MSCs) transplantation was associated with remyelination, inflammation suppression and oligodendrocyte precursor cells regeneration. Clinical trials indicated that 70% of the patients with MS showed disease stabilization following MSCs administration.
Conclusion: Although MSC therapy has showed to be effective in the improvement of some patients with MS, designing larger placebo-controlled clinical trials with MSCs expressing immune- regulators or MSCs-exosomes may provide a novel viewpoint in the treatment of MS.
Keywords: Mesenchymal stem cells, multiple sclerosis, cellular therapy, remyelination, stabilization, transplantation.
Current Stem Cell Research & Therapy
Title:Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Volume: 16 Issue: 8
Author(s): Zahra Esmaeilizade, Bahar Mohammadi, Mir Davood Omrani, Sayyed Mohammad Hossein Ghaderian, Masoumeh Rajabibazl and Zahra Fazeli*
Affiliation:
- Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Mesenchymal stem cells, multiple sclerosis, cellular therapy, remyelination, stabilization, transplantation.
Abstract:
Aim: Different studies have been performed to investigate stem cell administration as a promising tool for recovery of injured tissue in multiple sclerosis (MS), the most common demyelinating disease.
Methods: In the present systematic review, the electronic databases of PubMed and ScienceDirect were searched to screen English language studies published until April 2020.
Results: The results obtained from experimental autoimmune encephalomyelitis (EAE) animals revealed that modified mesenchymal stem cells (MSCs) transplantation was associated with remyelination, inflammation suppression and oligodendrocyte precursor cells regeneration. Clinical trials indicated that 70% of the patients with MS showed disease stabilization following MSCs administration.
Conclusion: Although MSC therapy has showed to be effective in the improvement of some patients with MS, designing larger placebo-controlled clinical trials with MSCs expressing immune- regulators or MSCs-exosomes may provide a novel viewpoint in the treatment of MS.
Export Options
About this article
Cite this article as:
Esmaeilizade Zahra, Mohammadi Bahar , Omrani Davood Mir , Ghaderian Mohammad Hossein Sayyed , Rajabibazl Masoumeh and Fazeli Zahra *, Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review, Current Stem Cell Research & Therapy 2021; 16 (8) . https://dx.doi.org/10.2174/1574888X16666210208162318
DOI https://dx.doi.org/10.2174/1574888X16666210208162318 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders
Current Drug Targets Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy
Current Bioactive Compounds Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Differential Kinetics and Inhibition of Purified Recombinant Tyrosine Kinase 2 (TYK-2) and Its Catalytic Domain JH-1
Protein & Peptide Letters Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets